TrialDiabetes, metabolic syndrome and obesity : targets and therapy2022

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial.

Deepa Joshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.